<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00178191</url>
  </required_header>
  <id_info>
    <org_study_id>10466</org_study_id>
    <secondary_id>1R21AG025490-01</secondary_id>
    <nct_id>NCT00178191</nct_id>
  </id_info>
  <brief_title>Randomized Trial for Botox Urinary Incontinence</brief_title>
  <official_title>A Randomized Trial of Botox for Severe Urge Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how effective Botox is in reducing the amount of
      urine leaked and which dose of Botox is more effective and safe in those who have urinary
      urge incontinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of urinary incontinence in the US ranges from 3-14% with epidemiologic
      estimates ranging widely.1 Most urinary incontinence can be categorized into stress urinary
      incontinence (SUI) or UUI with UUI remaining more common and debilitating than SUI.2 A major
      cause of UUI is overactive bladder or detrusor instability (DI), and while DI is very common,
      its etiology remains unknown. DI is often successfully managed with behavioral therapy,
      physical therapy, medications and surgery with the most effective therapy being
      anticholinergic medication.2 However, side effects including dry mouth, and constipation
      often lead to discontinuation of these drugs. In addition, many patients fail anticholinergic
      medication and have persistent urinary leakage. Women who fail these treatments have limited
      options.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Episodes/Day</measure>
    <time_frame>9 months</time_frame>
    <description>number of incontinence episodes/day</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>200 units Botox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 units Botulinum-A toxin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 units Botox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 units Botulinum-A toxin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bladder diary</intervention_name>
    <description>3-day bladder diary</description>
    <arm_group_label>200 units Botox</arm_group_label>
    <arm_group_label>300 units Botox</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Incontinence Quality of Life questionnaires</description>
    <arm_group_label>200 units Botox</arm_group_label>
    <arm_group_label>300 units Botox</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urodynamics</intervention_name>
    <description>Urodynamics</description>
    <arm_group_label>200 units Botox</arm_group_label>
    <arm_group_label>300 units Botox</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pad weight</intervention_name>
    <description>Pad weight</description>
    <arm_group_label>200 units Botox</arm_group_label>
    <arm_group_label>300 units Botox</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects must have ALL of the following:

          -  Completed a routine evaluation of incontinence (urodynamics, bladder diaries, and pad
             weights) through the urogynecology clinic at SMH within 3 months of the screening
             visit

          -  Symptoms of urge incontinence associated with leakage on bladder diary

          -  24-hour pad weight &gt;100 cc's (volume requiring multiple daily diaper changes)

          -  Absence of a bladder infection or other condition that could explain urinary leakage

          -  Absence of stress incontinence or a cough leak point pressure &gt; 100 cm H2O on
             cystometry (this correlates with mild stress incontinence)

          -  Failed anticholinergic therapy

          -  Willingness and ability to perform intermittent clean catheterization (due to the risk
             of prolonged urinary retention from Botox)

          -  The ability and willingness to return for surveillance evaluations

          -  A negative urine pregnancy test if at risk for pregnancy

          -  Competent to give signed consent and complete all of the study measures

        Exclusion Criteria:

          -  Children (&lt; 21 years old), pregnant women and prisoners

          -  History of carcinoma of the bladder

          -  Absence of a measurable detrusor contraction on a pressure flow micturition study

          -  A foreign body in the bladder or other correctable etiology for the UUI

          -  Prior documented resistance to Botox

          -  Gross fecal incontinence (due to confounding effects on pad weights and counts)

          -  Known allergy to lidocaine or related compounds (used for local analgesia)

          -  Known allergy to or inability to take both Bactrim DS or Ciprofloxacin (used for
             urinary tract infection prophylaxis)

          -  Current use of an aminoglycoside or preparing for general anesthesia within 1 week
             (risk of synergetic effects

          -  Known neurologic conditions such as Parkinson's disease, myasthenia gravis, multiple
             sclerosis, autonomic dysfunction, Lambert-Eaton syndrome, Amyotrophic Lateral
             Sclerosis or other neurologic disorder that may impact urinary function or the effect
             of Botox.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael K Flynn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <results_first_submitted>June 12, 2009</results_first_submitted>
  <results_first_submitted_qc>July 31, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2009</results_first_posted>
  <last_update_submitted>September 27, 2011</last_update_submitted>
  <last_update_submitted_qc>September 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Michael Flynn</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>onabotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started June, 2005 and completed Dec, 2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>200 Units Botox</title>
          <description>200 units Botulinum-A toxin</description>
        </group>
        <group group_id="P2">
          <title>300 Units Botox</title>
          <description>300 units Botulinum-A toxin</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>200 Units Botox</title>
          <description>200 units Botulinum-A toxin</description>
        </group>
        <group group_id="B2">
          <title>300 Units Botox</title>
          <description>300 units Botulinum-A toxin</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.20" spread="10.65"/>
                    <measurement group_id="B2" value="61.72" spread="13"/>
                    <measurement group_id="B3" value="74.14" spread="11.01"/>
                    <measurement group_id="B4" value="70" spread="13.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Episodes/Day</title>
        <description>number of incontinence episodes/day</description>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>200 Units Botox</title>
            <description>200 units Botulinum-A toxin</description>
          </group>
          <group group_id="O2">
            <title>300 Units Botox</title>
            <description>300 units Botulinum-A toxin</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Episodes/Day</title>
          <description>number of incontinence episodes/day</description>
          <units>number</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.9687"/>
                    <measurement group_id="O2" value="3.52" spread="0.95"/>
                    <measurement group_id="O3" value="8.7" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>200 Units Botox</title>
          <description>200 units Botulinum-A toxin</description>
        </group>
        <group group_id="E2">
          <title>300 Units Botox</title>
          <description>300 units Botulinum-A toxin</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Please see published manuscripts for additional details</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Michael Flynn</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-273-3232</phone>
      <email>Michaelk_flynn@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

